Wednesday, July 16, 2014

A Potential New Treatment For Childhood Epilepsy (BCECTS or Rolandic Epilepsy

A Potential New Treatment For Childhood Epilepsy

Posted Jul 16 2014 in Grants made in 2014 / News from Epilepsy Research UK
Diagram depicting the biofeedback loop. Ref: www.counsellingpsychologist.ie
EEG-biofeedback is a non-invasive learning strategy that can enable a person to alter his/her brain wave activity.  It has already been shown to be a safe and effective therapeutic option for some adults with epilepsy, but as yet there are no data available for children.Mrs Gina Parker and colleagues, at Birmingham Children’s Hospital NHS Trust, have been awarded £9,965 over 12 months, for pilot grant entitled Feasibility of EEG-biofeedback as a potential treatment for benign childhood epilepsy with centro-temporal spikes (BCECTS), in which they will assess the feasibility of using EEG-biofeedback as a therapeutic tool in children with BCECTS.
BCECTS (or Rolandic epilepsy) is the most common childhood epilepsy syndrome, but because seizures often occur at night, and are usually ‘outgrown’ in adolescence, it is often left untreated. Research now suggests that disruption to sleep during BCECTS can cause memory problems, and so the need to treat is being reviewed. Many parents are reluctant to have their child take anti-epileptic drugs (which can have pronounced side effects), especially when their seizures don’t obviously affect their daily life, and so a non-invasive approach would be very welcome.
During the study the team will recruit children with a diagnosis of BCECTS, who are not being prescribed any medication. Each child will be asked to attend a neurology appointment, where they will undergo a baseline 24-hour EEG assessment. Their EEG activity will be analysed on-line; and it will then be used to drive a video game, which will be displayed on a screen for the child to see. The child will then be asked to ‘work the video with their brain’; and the system will be set up so that the video game moves faster when the brain is relaxed. In this way the child will be trained to maintain a state of brain relaxation (less prone to seizures), and they will be able to see when they are achieving this state. The children will attend regular 30-minute training sessions with for six weeks, and they will receive video feedback every week. The researchers will compare the ‘current’ EEG to the baseline 24-hour EEG at specific time points during training, in order to measure a child’s progress. They will also compare the frequency of EEG abnormalities during the 24-hour recording at baseline and at the end of the study, to see if there has been any reduction.
If successful, this pilot grant will hopefully prompt larger studies into EEG-biofeedback as a new, non-invasive treatment for BCECTS.

Epilepsy Therapeutics in Major Developed Markets to 2019 - New AEDs with Novel Mechanisms of Action Signal a Shift in Treatment Patterns

July 15, 2014, 3:58 p.m. EDT

Epilepsy Therapeutics in Major Developed Markets to 2019 - New AEDs with Novel Mechanisms of  Action Signal a Shift in Treatment Patterns


LONDON, July 15, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:

Epilepsy Therapeutics in Major Developed Markets to 2019 - New AEDs with Novel Mechanisms of Action Signal a Shift in Treatment Patterns

https://www.reportbuyer.com/product/2052297/Epilepsy-Therapeutics-in-Major-Developed-Markets-to-2019---New-AEDs-with-Novel-Mechanisms-of-Action-Signal-a-Shift-in-Treatment-Patterns.html

Epilepsy Therapeutics in Major Developed Markets to 2019 - New AEDs with Novel Mechanisms of Action Signal a Shift in Treatment Patterns

Summary

GBI Research has released its pharma research, "Epilepsy Therapeutics in Major Developed Markets to 2019 - New AEDs with Novel Mechanisms of Action Signal a Shift in Treatment Patterns", which provides in-depth analysis of epilepsy market within the eight major developed markets of the US, UK, France, Germany, Italy, Spain, Japan and Canada. The report provides an estimation of the market size for 2012, along with market forecasts to 2019. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of the pipeline, and deal analysis.

The value of the epilepsy market in the major developed markets amounted to an estimated $3.4 billion in 2012 and is expected to register a Compound Annual Growth Rate (CAGR) of 3.9% to reach $4.5 billion by 2019. This modest growth is attributed to the recent approval of drugs with novel mechanisms of action that are expected to offer more therapeutic options to prescribers. The US takes major share of 55% of the global epilepsy market. In the US, three new anti-epileptic drugs have been approved since 2012: Trobalt, Aptiom, and Fycompa and another, brivaracetam, is expected also to be launched during the forecast period. Of these, Trobalt and Fycompa have novel mechanisms of action and improved safety and tolerability that elicited significant interest from prescribers. Continued uptake of second- and third-generation anti-epileptic drugs is also expected to contribute towards revenues in these eight regions. However, the epilepsy market could face the restricting influence of generic competition as a result of recent patent expiries in all major markets of two key branded drugs, Keppra and Lamictal.

Scope

- A brief introduction to epilepsy, including disease pathogenesis, risk factors, diagnosis and treatment options
- In-depth analysis of major marketed products covering product performance, product life-cycle and a heat map depicting comparative analysis of safety and efficacy parameters
- A comprehensive review of the epilepsy pipeline which includes individual analysis of promising late-stage pipeline drugs that are most likely to enter the market during the forecast period. The pipeline is analyzed on the basis of Phase distribution, molecule type and molecular target
- Additional clinical trial analysis by Phase, trial size, trial duration and program failure rate for each molecule type and mechanism of action
- Multi-scenario forecasts of the epilepsy market over the 2012–2019 period in the eight major developed markets
- In-depth analysis of licensing and co-development agreements and an overview of key agreements that could impact growth trends
- Key drivers and restraints that have had and are expected to have a significant impact upon the market

Reasons to buy

- Align your product portfolio to markets with high growth potential
- Develop market entry and expansion strategies by identifying the potential regions and therapeutic segments poised for strong growth
- Devise effective, tailored strategies for each country through the understanding of key drivers and barriers in the anti-epileptic drugs market
- Develop key strategic initiatives based upon an understanding of key focus areas and leading companies
- Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships 

1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 7
1.2 List of Figures8
2 Introduction 9
2.1 Disease Overview 9
2.2 Epidemiology 9
2.3 Symptoms 11
2.4 Etiology 11
2.5 Pathophysiology 12
2.6 Co-morbidities/Complications 12
2.7 Diagnosis 12
2.8 Prognosis 13
2.9 Treatment Efficacy 13
2.10 Treatment Options 14
2.10.1 Ion Channel Modulators 14
2.10.2 GABA-ergic Facilitation 15
2.10.3 Excitatory Amino Acid Inhibitors 15
2.10.4 Synaptic Modulators 15
2.11 Non-pharmacological Management 15
2.11.1 Lobectomy and Lesionectomy 15
2.11.2 Ketogenic Diet and Modified Atkins Diet 15
2.11.3 Vagus Nerve Stimulation 16
3 Epilepsy Therapeutic Landscape 17
3.1 Overview 17
3.2 Lyrica (pregabalin) 17
3.3 Lamictal (lamotrigine) 18
3.4 Keppra (levetiracetam) 19
3.5 Zonegran (zonisamide) 21
3.6 Vimpat (lacosamide) 22
3.7 Aptiom/Zebinix (eslicarbazepine acetate) 24
3.8 Fycompa (perampanel) 24
3.9 Trobalt/Potiga (ezogabine/retigabine) 25
3.10 Banzel/Inovelon (rufinamide) 26
3.11 Comparative Efficacy and Safety of Marketed Products 26
4 Pipeline for Epilepsy Therapeutics 29
4.1 Overall Pipeline 29
4.2 Pipeline by Mechanism of Action 31
4.3 Clinical Trials 32
4.3.1 Failure Rate 32
4.3.2 Patient Enrolment and Clinical Trial Size 34
4.3.3 Clinical Trial Duration 36
4.4 Promising Pipeline Candidates 38
4.4.1 Brivaracetam – UCB 38
4.4.2 Ganaxolone – Marinus Pharmaceuticals 38
5 Epilepsy Therapeutics Market Forecast to 2019 39
5.1 Geographical Markets 39
5.1.1 Major Developed Markets 39
5.1.2 The US 40
5.1.3 Top Five EU Countries 43
5.1.4 Japan 46
5.1.5 Canada 48
5.2 Drivers and Barriers 50
5.2.1 Drivers 50
5.2.2 Barriers 50
6 Deals and Strategic Consolidations 52
6.1 Deals Analysis 52
6.2 Research and Development Co-development Agreements 54
6.3 Research and Development Licensing Agreements 55
7 Appendix 57
7.1 Abbreviations 57
7.2 References 58
7.3 References for Heat Maps 62
7.4 Pipeline Products by Phase 63
7.4.1 Discovery 63
7.4.2 Preclinical 63
7.4.3 IND-filed and Phase 0 64
7.4.4 Phase I 65
7.4.5 Phase II 65
7.4.6 Phase III 66
7.4.7 Pre-registration 66
7.5 Market Forecasting Data Tables to 2019 67
7.5.1 Major Developed Markets 67
7.5.2 US 67
7.5.3 UK 67
7.5.4 France 68
7.5.5 Germany 68
7.5.6 Italy 68
7.5.7 Spain 69
7.5.8 Japan 69
7.5.9 Canada 69
7.6 Research Methodology 70
7.6.1 Coverage 70
7.6.2 Secondary Research 70
7.6.3 Primary Research 70
7.6.4 Therapeutic Landscape 71
7.6.5 Geographical Landscape 74
7.6.6 Pipeline Analysis 74
7.7 Expert Panel Validation 74
7.8 Contact Us 74
7.9 Disclaimer 74

1.1 List of Tables
Table 1: Epilepsy Therapeutics, Global, Types of Seizures, 2013 9
Table 2: Epilepsy Therapeutics, Heat Maps for Efficacy and Safety of Marketed Products, References 62
Table 3: Epilepsy Therapeutics, Global, Pharmaceutical Pipeline (Discovery), 2013 63
Table 4: Epilepsy Therapeutics, Global, Pharmaceutical Pipeline (Preclinical), 2013 63
Table 5: Epilepsy Therapeutics, Global, Pharmaceutical Pipeline (IND/CTA-filed), 2013 64
Table 6: Epilepsy Therapeutics, Global, Pharmaceutical Pipeline (Phase I), 2013 65
Table 7: Epilepsy Therapeutics, Global, Pharmaceutical Pipeline (Phase II), 2013 65
Table 8: Epilepsy Therapeutics, Global, Pharmaceutical Pipeline (Phase III), 2013 66
Table 9: Epilepsy Therapeutics, Global, Pharmaceutical Pipeline (Pre-registration), 2013 66
Table 10: Epilepsy Therapeutics, Major Developed Markets, Market Forecast, 2012–2019 67
Table 11: Epilepsy Therapeutics, US, Market Forecast, 2012–2019 67
Table 12: Epilepsy Therapeutics, UK, Market Forecast, 2012–2019 67
Table 13: Epilepsy Therapeutics, France, Market Forecast, 2012–2019 68
Table 14: Epilepsy Therapeutics, Germany, Market Forecast, 2012–2019 68
Table 15: Epilepsy Therapeutics, Italy, Market Forecast, 2012–2019 68
Table 16: Epilepsy Therapeutics, Spain, Market Forecast, 2012–2019 69
Table 17: Epilepsy Therapeutics, Japan, Market Forecast, 2012–2019 69
Table 18: Epilepsy Therapeutics, Canada, Market Forecast, 2012–2019 69

1.2 List of Figures
Figure 1: Epilepsy Therapeutics, Epidemiology, Major Developed Markets, 2012 10
Figure 2: Epilepsy Therapeutics, Major Developed Markets, Approved Anti-epileptic Drugs, 2013 14
Figure 3: Epilepsy Therapeutics, Lyrica, Global, Revenue ($bn), 2013 18
Figure 4: Epilepsy Therapeutics, Lamictal, Global, Revenue ($m), 2009–2013 19
Figure 5: Epilepsy Therapeutics, Keppra, Global, Revenue ($bn), 2009–2013 20
Figure 6: Epilepsy Therapeutics, Zonegran, Global, Revenue ($m), 2009–2013 21
Figure 7: Epilepsy Therapeutics, Vimpat, Global, Revenue ($m), 2009–2013 23
Figure 8: Epilepsy Therapeutics, Global, Comparative Safety and Efficacy of Marketed Products (Heat Map), 2013 27
Figure 9: Epilepsy Therapeutics, Global, Overall Pipeline Analysis, 2013 30
Figure 10: Epilepsy Therapeutics, Global, Pipeline Analysis, by Mechanism of Action, 2013 31
Figure 11: Epilepsy Therapeutics, Global, Pipeline, Clinical Trial Failure Rate, 2013 33
Figure 12: Epilepsy Therapeutics, Global, Pipeline, Clinical Trial Size, 2013 35
Figure 13: Epilepsy Therapeutics, Global, Pipeline, Clinical Trial Duration, 2013 37
Figure 14: Epilepsy Therapeutics, Major Developed Markets, Treatment Usage Pattern and Market Size, 2012–2019 40
Figure 15: Epilepsy Therapeutics, US, Treatment Usage Pattern, ACoT and Market Size, 2012–2019 42
Figure 16: Epilepsy Therapeutics, Top Five EU Countries, Treatment Patterns ('000), 2012–2019 43
Figure 17: Epilepsy Therapeutics, Top Five EU Countries, Annual Cost of Treatment ($), 2012–2019 44
Figure 18: Epilepsy Therapeutics, Top Five EU Countries, Market Size ($m), 2012–2019 45
Figure 19: Epilepsy Therapeutics, Japan, Treatment Usage Pattern, ACoT and Market Size, 2012–2019 47
Figure 20: Epilepsy Therapeutics, Canada, Market Size, 2012–2019 49
Figure 21: Epilepsy Therapeutics, Deals by Region, Value and Year, 2006–2013 52
Figure 22: Epilepsy Therapeutics, Deals by Molecule Type and Mechanism of Action, 2006–2013 53
Figure 23: Epilepsy Therapeutics, Co-development Deals, Territory, 2006–2013 54
Figure 24: Epilepsy Therapeutics, Licensing Deals, by Territory, 2006–2013 55
Figure 25: GBI Research Market Forecasting Model 73


Read the full report:Epilepsy Therapeutics in Major Developed Markets to 2019 - New AEDs with Novel Mechanisms of Action Signal a Shift in Treatment Patternshttps://www.reportbuyer.com/product/2052297/Epilepsy-Therapeutics-in-Major-Developed-Markets-to-2019---New-AEDs-with-Novel-Mechanisms-of-Action-Signal-a-Shift-in-Treatment-Patterns.html
Website: www.reportbuyer.com
SOURCE ReportBuyer

Tuesday, July 8, 2014

Shop at Bravelets for Epilepsy Awareness Jewelry and $10 of Each Purchase Goes to Angels4Epilepsy, Inc.


Here is another way you can help Jamie and Danielle deliver to more children with epilepsy and/or asthma!  Shop at Bravelets for Epilepsy Awareness Jewelry and $10 of Each Purchase Goes to Angels4Epilepsy, Inc.

Sunday, July 6, 2014

Angels4Epilepsy, Inc. & Asthma Too: Young Sisters Send Package to Child with Epilepsy


The girls sent an El Paso PetSmart Donated Chase Pup, a copy of Jamie's book (I Have Epilepsy It Doesn't Have Me on Amazon) and an USB medical history bracelet to this little cutie who has epilepsy.

Angels4Epilepsy, Inc. & Asthma Too Delivers a Kohls Cares for Kids' Snoopy to Another Child


Sisters, Jamie and Danielle, delivered a Snoopy to this adorable little one.  As you can see, she seems to have made a new friend!

Sunday, June 29, 2014

11 Year Old Used Kohls Cares for Kids Gift Card Win to Purchase More for Kids with #Epilepsy and #Asthma


Jamie used her Kohls Cares for Kids gift card she won along with additional funds to purchase more stuffed animals to give to kids with #Epilepsy and #Asthma.

Thursday, June 26, 2014

Angels4Epilepsy, Inc. & Asthma Too Delivers to Evansville, Indiana


Angels4Epilepsy, Inc. & Asthma Too Delivers to Evansville, Indiana thanks to the girls' latest volunteer, Bea!  Thank you so much for all you have done with delivering to the hospital in Evansville and the Ronald McDonald House and your fundraising visions!

Friday, June 6, 2014

Shop at Amazon and Angels4Epilepsy, Inc will Receive .5%



You can donate to Angels4Epilepsy, Inc. via Amazon Smile! When you shop via this link, select Angels4Epilepsy, Inc as your charity and we'll receive .5%!  There is no cost to you either so it's a win-win!  Help bring smiles to little children across the country battling epilepsy and/or asthma!

http://smile.amazon.com/ref=smi_ext_fbp_lds_smi

Thursday, May 22, 2014

Angels4Epilepsy, Inc. & Asthma Too Sisters Deliver to Another Child with Epilepsy


Another cutie from our Angels4Epilepsy, Inc. & Asthma Too support group holding her donated PetSmart stuffed animal along with the book Jamie wrote (found on Amazon) about her journey with epilepsy. We also included an USB medical history bracelet to help keep track of medical records.

http://www.amazon.com/Have-Epilepsy-It-Doesnt-Me/dp/1475165846/ref=as_li_ss_til?tag=stayouyoutipa-20&linkCode=w01&linkId=XWCDR7A5DD3QLNYR&creativeASIN=1475165846

Can cannabis prevent childhood seizures? Experts unsure


Some parents of children with severe epilepsy say that cannabis helps prevent their children's seizures, but experts caution that it remains unproven whether using the drug to treat epilepsy is safe or effective.

One mother in Colorado turned to cannabis to treat her daughter's intractable seizures, which had started when her daughter was 3 months old, and occurred as often as 50 times a day, according to a new report of the girl's case, published online May 22 in the journal Epilepsia.

Read the rest of the article about medical marijuana/cannabis for epilepsy here.

Wednesday, May 21, 2014

Angels4Epilepsy, Inc. & Asthma Too: Sisters Deliver to Another Child with #Epilepsy and/or Asthma


Another adorable child from our Angels4Epilepsy, Inc. & Asthma Too support group holding his Easter bunny from Build-A-Bear the girls sent to bring a smile in time for Easter along with the book Jamie wrote (found on Amazon) about her journey with epilepsy. We also included an USB medical history bracelet to help keep track of medical records.

http://www.amazon.com/Have-Epilepsy-It-Doesnt-Me/dp/1475165846/ref=as_li_ss_til?tag=stayouyoutipa-20&linkCode=w01&linkId=XWCDR7A5DD3QLNYR&creativeASIN=1475165846

Monday, May 19, 2014

@Angels4Epilepsy : Young Sisters Deliver to Another Child with #Epilepsy and/or #Asthma

Another cutie receiving her stuffed animal from Build-A-Bear, Jamie's book about her journey with epilepsy and an USB bracelet from the girls that supports children with epilepsy and/or asthma.


Tuesday, May 13, 2014

Another Child with Epilepsy and/or Asthma Receives Gifts from Angels4Epilepsy, Inc. & Asthma Too Sisters

Another adorable child from our support group holding his Easter bunny from Build-A-Bear the girls sent him to bring a smile in time for Easter along with the book Jamie wrote (found on Amazon) about her journey with epilepsy.  We also included an USB medical history bracelet to help keep track of medical records.





Thursday, May 8, 2014

Angels4Epilepsy, Inc. & Asthma Too Sisters Deliver to El Paso Children's Hospital's EEG Unit

The girls delivered 25 of the donated PetSmart stuffed animals along with two EEG felt dolls for educational purposes to the El Paso Children's Hospital today.  Every time we make a delivery, they both say how much they love this!


Friday, May 2, 2014

UCB Offers 30 One-Time Scholarships of Up to $5,000 for Student/Family/Caregiver Living with Epilepsy


The UCB Family Epilepsy Scholarship Program™ offers educational scholarships to people living with epilepsy, family members and caregivers who demonstrate academic and personal achievement. This year marks the 10th anniversary of the scholarship program. Since 2005, UCB has awarded $1,400,000 in scholarships to more than 275 deserving people who have applied their awards to undergraduate and graduate studies.

To apply and learn more, click here:  Epilepsy Scholarships

Angels4Epilepsy, Inc. & Asthma Too Delivers to Another Child with Epilepsy and/or Asthma


I've been behind in posting new pictures of the beautiful children with #epilepsy and/or #asthma we have been sending gift packages too.  Here is another one that received a special one for Easter.  Isn't she a doll?

We are a 501(c)(3) and would greatly appreciate donations.  Thank you!

Monday, April 7, 2014

There is Nothing Bummer About the Bummer Bear

 

Isn't this bear adorable?  He's a bear that is unique as the condition in which you might want to cheer up that special someone.  Of course, we were drawn to it because they even have an epilepsy related one!

http://www.bummerbears.com/products/special-order-bummer-bear

Another Child with Epilepsy and/or Asthma Receives Stuffed Animal, Book & Bracelet from Young Sisters on a Mission


The girls were happy to see this beautiful young girl with her Build-A-Bear stuffed animal the girls sent.  She also received a copy of Jamie's book about her epilepsy and an USB medical history bracelet.

Her book is available on Amazon:



Thursday, March 13, 2014

Young Sisters Deliver to Another Child with #Epilepsy - @Angels4Epilepsy

We are happy to share this cutie with his very much loved PetSmart donated Chase dressed as Superman along with his copy of Jamie's book, "I Have Epilepsy. It Doesn't Have Me" and a usb medical history bracelet.  His mom even shared a video that was priceless! <3